SensNews Jan 2016

Sensor100

January 2016

Glaxo Smith Kline and Qualcomm Reported inTalks to

Set up JointVenture

GlaxoSmithKline Plc and Qualcomm Inc. are in discussions to form a joint venture as

Glaxo looks for ways to develop medical technology, according to people with knowl-

edge of the matter. The talks are preliminary and nothing has been decided, said the

people, who asked not to be named because the deliberations are private.

January 20

ScrippsWired for Health study results show no clinical

or economic benefit from digital health monitoring

MobileHealthNews reported that the six-month randomized control trial found no

short-term benefit in health costs or outcomes for patients monitoring their health

with connected devices. Three groups of patients - diabetics, hypertensives and those

with arrythmias - were given monitoring devices connected to smart phones and their

physicians. “It was a bit disappointing, but remember, this was the first multisensor trial

that’s ever been reported, so in that respect it was a pioneering effort,” study author

and STSI Director Dr. Eric Topol told MobiHealthNews.“And you know, it was very dif-

ficult because we had these three different sensors, glucose, blood pressure, and heart

rhythm, and a lot of patients had all three problems or two of them, and had to have a

dashboard created.There are a lot of logistical challenges there.”

19 January

Noninvasive Uric acid Monitoring Device using Near-In-

frared Spectroscopy

A project at the University of Central Florida

College of Medicine has examined the feasibility

of a near infra-red sensor to monitor uric acid,

which is found in joints affected by gout; over 8

million Americans suffer from this painful dis-

ease. This approach offers a cost-effective and

portable near-infrared (NIR) spectroscopy based

device that can provide quick, noninvasive, and

preventative way to monitor the patient’s uric

acid level.

November 20, 2015